Company Overview of Genta Incorporated
Genta Incorporated, a biopharmaceutical company, engages in the identification, development, and commercialization of novel drugs for the treatment of cancer and related diseases. Its products include Tesetaxel, a novel taxane compound that has completed Phase 2 trials in patients with advanced gastric cancer, breast cancer, bladder cancer, prostate cancer, and melanoma. The company is also developing G4544a, an orally bioavailable gallium-containing compound, which has completed a single-dose Phase 1 clinical study for the treatment of diseases associated with accelerated bone loss. In addition, it markets Ganite, an intravenous formulation of gallium nitrate to treat cancer-related hyperca...
200 Connell Drive
Berkeley Heights, NJ 07922
Founded in 1988
Key Executives for Genta Incorporated
Genta Incorporated does not have any Key Executives recorded.
Genta Incorporated Key Developments
Genta Incorporated Receives Approval from the Drug Regulatory Authority of the People's Republic of China to Start Clinical Trials with tesetaxel
Jul 30 12
On July 30, 2012, Genta Incorporated announced that it has received formal notice from the drug regulatory authority of the People's Republic of China (SFDA) that the company has received approval to start clinical trials with tesetaxel, its lead clinical compound, in China. SFDA has requested and approved a dose-ranging study of the combination of capecitabine plus tesetaxel, up to and including the dose used in a pivotal randomized trial (known as TESEGAST), as well as subsequent participation by China in the TESEGAST study. The TESEGAST study is designed to evaluate the safety and activity of tesetaxel plus capecitabine compared with capecitabine plus placebo in patients with advanced gastric cancer. Gastric cancer is the second most common tumor type in China.
Genta Incorporated Restates Earnings Results for the First Quarter Ended March 31, 2012
Jul 27 12
Genta Incorporated restated earnings results for the first quarter ended March 31, 2012. For the period, the company restated net loss was $10,664,000 or $0.01 basic and diluted per share against net income of $5,234,000 as reported.
Genta Incorporated to Report Q2, 2012 Results on Aug 13, 2012
Jul 12 12
Genta Incorporated announced that they will report Q2, 2012 results on Aug 13, 2012
Similar Private Companies By Industry
Recent Private Companies Transactions